Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts

摘要

BackgroundActive surveillance (AS) is increasingly accepted for managing low-risk prostate cancer, yet there is no consensus about implementation. The lack of consensus is due in part to uncertainty about risks of disease progression, which have not been systematically compared or integrated across AS studies with variable surveillance protocols and dropout to treatment.